NCT06264557已完成不适用
A Multicenter, Prospective, Comparative, Randomized, Independent Rater-blind, Superiority Clinical Trial to Compare the Safety and Efficacy of the Cognitive Therapy Software 'SUPERBRAIN DEX' With a Control Group for Patients With MCI
Rowan18 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2024年1月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 140
- 试验地点
- 18
- 主要终点
- K-RBANS
研究概览
简要总结
Cognitive therapy software for improving cognitive function for patients with mild cognitive impairment
详细描述
A multicenter, prospective, comparative, randomized, independent rater-blind, superiority, pivotal clinical trial to compare the safety and efficacy of the Cognitive therapy software 'SUPERBRAIN DEX' for improving cognitive function with a control group for patients with mild cognitive impairment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •50 - 85years old
- •Those who meet all of the National Institute on Aging-Alzheimer's Association (NIA-AA) key clinical criteria below that may suspect mild cognitive impairment caused by Alzheimer's disease as of the screening date
- •Concern of the subject or guardian about the deterioration of cognitive function compared to before
- •More than one cognitive impairment
- •Maintaining the independence of overall daily life functions
- •It's not dementia
- •In at least one of the following neuropsychological tests conducted within one year of the screening date, the delayed recall score in the memory area was 'average -1' according to the standard score table corrected for education level and age.
- •Seoul Neuropsychological Screening Battery 2nd edition (SNSB-II)
- •Korean version of Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K)
- •Literacy Independent Cognitive Assessment (LICA)
- •A person whose Korea-Mini Mental State Examination-2 (K-MMSE-2) score corresponds to "Average-1.5 standard deviation or higher" according to the standard score table corrected for education level and age as of the screening date
- •Those with a Global Clinical Dementia Rating (CDR) score of 0.5 and a memory item score of 0.5 or 1 as of the screening date
- •A person who has a guardian in regular contact with the subject
- •Defined to be able to support subjects during the clinical trial (compliance supervision and subject status reporting) and spend at least 8 hours per week with subjects
- •A person who is taking drugs (donepezil, galantamine, ribastigmine, memantine) for the purpose of improving cognitive function is taking drugs stably for at least 12 weeks as of the screening date
- •Those who have no difficulty using tablet PCs
- •A person who voluntarily decides to participate in this clinical trial and agrees to the subject's explanation and consent in writing
- •Those who are willing to comply with the clinical trial plan
排除标准
- •Those diagnosed with dementia (including Alzheimer's disease, vascular dementia, infections of the central nervous system (e.g., Human Immunodeficiency Virus (HIV), syphilis, etc.), Creutzfeld-Jacob disease (Creutzfeld-Jacob disease), Pick disease, Huntington's disease, Parkinson's disease, etc.) as of the screening date
- •Those who have a history of diagnosing significant neurological diseases affecting cognitive function within one year of the screening date (e.g., stroke, multiple sclerosis, severe head trauma with loss of consciousness, normal cerebral hydrocephalus, epilepsy, brain tumors, cerebral infarction, spinal cord infarction or central nervous system infection)
- •Based on the screening date, major depressive disorder, bipolar disorder, schizophrenia, A person diagnosed with a serious mental illness such as drug addiction and alcoholism
- •Laboratory and/or vital signs tests as of the date of screening, any of the following
- •Those diagnosed with infectious or metabolic diseases that may cause cognitive decline in the subject (e.g., hypothyroidism, vitamin B12 deficiency, folate deficiency, neurotoxin, HIV)
- •Those with liver dysfunction (AST, ALT ≥ 3x upper limit of normal range) and/or renal dysfunction (serum creatinine ≥ 2x upper limit of normal range)
- •Those with uncontrolled hypertension (SBP > 180 mmHg) and/or diabetes (HbA1c > 11%)
- •Those who have severe or unstable cardiovascular disease (e.g., myocardial infarction, unstable angina, class III or IV heart failure by classification of the New York Heart Association (NYHA) within 24 weeks of the screening date)
- •Where the tester determines that he/she has a medical condition that may interfere with the completion of the clinical trial due to a serious or unstable physical condition (e.g., a history of malignant tumors within five years of the screening date (e.g., basal cell cancer and squamous cell carcinoma of the skin considered to have been completely resected and cured, cervical intraepithelial carcinoma, non-transparent prostate cancer, acute and severe asthma, active peptic ulcers, etc.)
- •If you can't walk, A person who can move using walking aids (e.g. walkers, canes, wheelchairs, etc.)
- •an illiterate patient who is unschooled (defined as unadmitted to a regular school)
- •Where the tester determines that a person does not have sufficient vision, hearing, language skills, motor skills, and comprehension to follow the examination procedures related to clinical trials
- •a person who is pregnant or nursing
- •For women of childbearing age, who do not agree with the medically permitted contraceptive method during the clinical trial
- •Hormonal contraception, intrauterine device (IUD) or intrauterine system (IUS), oviduct ligation, double blocking (male condom, female condom, cervical cap, a combination of contraceptive septum, contraceptive sponge-like blocking methods), a single blocking method with a combination of an alveolar agent
- •Those who are currently participating in other clinical trials or who have participated in other clinical trials within 90 days of screening
- •Other, ethical or clinical trial outcomes may be impacted and deemed inappropriate by the tester
研究组 & 干预措施
Treatment group
Experimental
Device : SB-100
Cognitive training will be conducted once a day, and it will take 15 to 30 minutes.
It consists of cognitive training and educational videos.
干预措施: SB-100 (Device)
Contol group
Other
Educational book : book of education on daily rules for preventing dementia
干预措施: Educational book (Other)
结局指标
主要结局
K-RBANS
时间窗: Baseline, 16 weeks after treatment
The closer the total score of 160 points, the worse the cognitive state is, and the closer it is to 40, the worse the cognitive state is
次要结局
- GDS-15(Baseline, 8 weeks after treatment, and 16 weeks after treatment)
- K-RBANS(Baseline, 8 weeks after treatment)
- K-MMSE-2(Baseline, 8 weeks after treatment, and 16 weeks after treatment)
- K-IADL(Baseline, 8 weeks after treatment, and 16 weeks after treatment)
- CDR-SB(Baseline, 8 weeks after treatment, and 16 weeks after treatment)
- PRMQ(Baseline, 8 weeks after treatment, and 16 weeks after treatment)
- QOL-AD(Baseline, 8 weeks after treatment, and 16 weeks after treatment)
- ADAS-Cog14(Baseline, 16 weeks after treatment)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
1 期
Computer-Based Therapy for Mild Cognitive ImpairmentMild Cognitive ImpairmentNCT00319943Posit Science Corporation48
已完成
不适用
Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1Neurofibromatosis Type 1NCT02944032Kristina Hardy103
撤回
不适用
The Therapeutic Effect of Computer-assisted Cognitive Function Training on Cognitive Dysphagia After StrokeDysphagiaCognitive ImpairmentStrokeNCT06215729Zeng Changhao
已完成
不适用
Impact of a Memory Group for Older Adults Reporting Memory DifficultiesMild Cognitive ImpairmentAlzheimer's DiseaseNCT01998711Bayside Health62
撤回
不适用
Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer SurvivorsCancer SurvivorCognitive/Functional EffectsBreast CancerNCT02166983Stanford University